


Tetrahydropalmatine

Cat. No.:	HY-N0300		
CAS No.:	2934-97-6		
Molecular Formula:	C ₂₁ H ₂₅ NO ₄		
Molecular Weight:	355.43		
Target:	Dopamine Receptor; Apoptosis		
Pathway:	GPCR/G Protein; Neuronal Signaling; Apoptosis		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro	DMSO : 6.67 mg/mL (18.77 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.8135 mL	14.0675 mL	28.1349 mL
		5 mM	0.5627 mL	2.8135 mL	5.6270 mL
10 mM		0.2813 mL	1.4067 mL	2.8135 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 0.67 mg/mL (1.89 mM); Clear solution				

BIOLOGICAL ACTIVITY

Description	Tetrahydropalmatine possesses analgesic effects. Tetrahydropalmatine acts through inhibition of amygdaloid release of dopamine to inhibit an epileptic attack in rats ^[1] .
IC₅₀ & Target	Dopamine ^[1]
In Vivo	Tetrahydropalmatine (THP), an active component isolated from corydalis (a Chinese herbal medicine), possesses analgesic effects. Picrotoxin treatment alone has a significant effect on the following activity measure: there is an increase in horizontal motion time (HMT), vertical motion time (VMT), clockwise turnings (CT), anticlockwise turning (ACT) and a decrease in freezing time (FT). Tetrahydropalmatine treatment alone causes a decrease in HMT, VMT and total distance traveled (TDT), but an increase in FT. Pretreatment of rats with an i.p. dose of 10 mg/kg or 15 mg/kg of Tetrahydropalmatine significantly attenuates the Picrotoxin-induced enhancement in HMT, VMT, CT, ACT and TDT, as well as reduction in FT. Another 48 rats under urethane anesthesia are randomly divided into six groups, each of eight rats. The s.c. injection of

Picrotoxin causes an increase in amygdaloid release of dopamine (DA), while i.p. injection of Tetrahydropalmatine at 10 mg/kg has an insignificant effect on amygdaloid release of DA. Again, the Picrotoxin-induced increase in amygdaloid release of DA is significantly attenuated by pretreatment with Tetrahydropalmatine. The Picrotoxin-induced augmented amygdaloid release of DA is almost completely abolished by pretreatment with Tetrahydropalmatine 30 min before s.c. injection of Picrotoxin^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Animal Administration ^[1]

Rats^[1]

Male Sprague-Dawley rats, weighing 250-320 g, are used in the present study. The animals are housed in a temperature-regulated (22±1°C) room on 12:12 h light/dark cycles with food and water available ad libitum. The light is turned on at 06:00 h and turned off at 18:00 h. At least two major groups of animals are studied. (1) Vehicle-treated rats: received an i.p. injection of 0.9% saline plus Picrotoxin (3-4 mg/kg, s.c.). (2) Tetrahydropalmatine-treated rats: receive an injection of Tetrahydropalmatine (10 mg/kg, i.p.) plus Picrotoxin (3-4 mg/kg, s.c.). The effects of s.c. administration of Picrotoxin or Tetrahydropalmatine on locomotor activity are assessed in unanesthetized rats. On the other hand, the effects of Picrotoxin or Tetrahydropalmatine on amygdaloid DA release are assessed in rats under urethane (1.4 g/kg, i.p.) anesthesia^[1]. Seventy-two unanesthetized rats are randomly divided into nine groups, each of eight rats. The animals are adapted to the behavior apparatus for 30 min before an injection of Picrotoxin (3 or 4 mg/kg, s.c.), Tetrahydropalmatine (10 or 15 mg/kg, i.p.) or saline. Then, the locomotor activities of these rats are recorded during the 30-min period following the injections^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Biomed Pharmacother. 2023 Nov 18:169:115887.
- J Anim Sci. 2022 Mar 5;skac069.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Chang CK, et al. DL-Tetrahydropalmatine may act through inhibition of amygdaloid release of dopamine to inhibit an epileptic attack in rats. *Neurosci Lett.* 2001 Jul 20;307(3):163-6.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA